<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302653</url>
  </required_header>
  <id_info>
    <org_study_id>L_9436</org_study_id>
    <nct_id>NCT00302653</nct_id>
  </id_info>
  <brief_title>Rasburicase in Tumor Lysis Syndrome</brief_title>
  <official_title>Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rasburicase is effective and safety in
      correcting hyperuricemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)</measure>
    <time_frame>24-48 hours after last dose of rasburicase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)</measure>
    <time_frame>28 (+- 3) days after the last dose of rasburicase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>During the study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rasburicase 0,20mg/Kg/Day once a day 3-7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasburicase</intervention_name>
    <description>Rasburicase 0,20mg/Kg/Day once a day 3-7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        List of inclusion Criteria:

          -  Acute hyperuricemia patients(uric acid&gt;8.0 mg/dl) before/during chemotherapy for
             hematologic malignancies.

        List of exclusion Criteria:

          -  Hypersensitivity to uricases or any of the excipients.

          -  Known history of hemolytic anemia (G6PD deficiency).

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaderson Lima</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi-aventis administrative office Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
    <mesh_term>Tumor Lysis Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

